Sogroya (somapacitan) / Novo Nordisk - LARVOL DELTA

Weekly long-acting growth hormone versus daily growth hormone therapy on quality of life, efficacy, and safety in children with short stature: a systematic review and meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "Available QoL data from two major trials indicated comparable improvements between treatment groups, with a trend toward greater clinical benefit in psychosocial domains observed for a higher dose of Somapacitan...By reducing injection frequency, LAGH offers the potential to enhance treatment convenience and adherence, which may translate into improved QoL. Further long-term studies are warranted to confirm these findings and to investigate formulation-specific effects."

Clinical • HEOR • Journal • Retrospective data • Review • IGF1

Treatment of growth hormone deficiency with long-acting growth hormones in children, adolescents and adults: Clinical evidence and practical considerations. (PubMed, Ann Endocrinol (Paris)) - "Three once-weekly LAGH products are currently available in the EU: lonapegsomatropin, somatrogon and somapacitan. With a focus on somapacitan, currently the only LAGH approved in France for both children and adults, the review discusses practical aspects of dosing and monitoring across age groups and addresses use in special populations and during the transition period from paediatric to adult care. Ongoing follow-up and real-world studies will further clarify long-term safety, adherence and metabolic outcomes."

Journal • Review • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric) • Pediatrics

Injection-site pain after switching from somatrogon to somapacitan in children reporting pain or discomfort during once-weekly growth hormone therapy: a prospective single-arm switch study. (PubMed, Front Endocrinol (Lausanne)) - "In children who reported injection-site pain or discomfort during somatrogon therapy and agreed to switch, pain scores and treatment preference improved after switching to somapacitan. These findings support considering a switch to another once-weekly GH formulation when injection-site pain affects treatment preference."

Journal • Brain Cancer • CNS Tumor • Endocrine Disorders • Growth Hormone Deficiency • Pain

Somapacitan in Children and Adolescents Born Small for Gestational Age: 2-Year REAL8 Results Including Switch From Daily GH (ESPE 2026) - No abstract available

Clinical • Small for Gestational Age

Somapacitan in Children and Adolescents with Noonan Syndrome: 2-Year REAL8 Results Including Switch from Daily GH (ESPE 2026) - No abstract available

Clinical • Genetic Disorders

Somapacitan in Children and Adolescents with Idiopathic Short Stature: 2-Year REAL8 Results Including Switch from Daily GH (ESPE 2026) - No abstract available

Clinical • Idiopathic Short Stature

When weekly LAGH falls short: Daily GH reversed excessive fat mass gain on Somapacitan. (ESPE 2026) - No abstract available

The impact of puberty on IGF-I SDS in children and adolescents with GHD receiving once-weekly somapacitan (ESPE 2026) - No abstract available

Clinical • IGF1

Clinical Study of Somapacitan in the Treatment of 32 Chinese Children with Growth Hormone Deficiency (ESPE 2026) - No abstract available

Clinical • Endocrine Disorders • Growth Hormone Deficiency

Four-year efficacy and safety of somapacitan treatment in children with growth hormone deficiency (GHD): results from the REAL 4 trial (ESPE 2026) - No abstract available

Clinical • Endocrine Disorders • Growth Hormone Deficiency

Real-world effectiveness and safety of Somapacitan in pubertal and prepubertal children with growth hormone deficiency (ESPE 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Endocrine Disorders • Growth Hormone Deficiency

Somapacitan in Children and Adolescents Born Small for Gestational Age: 2-Year REAL8 Results Including Switch From Daily GH (ESPE 2026) - No abstract available

Clinical • Small for Gestational Age

Baseline characteristics, treatment patterns and 12-month real-world effectiveness of somapacitan in patients with growth hormone deficiency (GHD): data from GloBE-Reg (ESPE 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Endocrine Disorders • Growth Hormone Deficiency

Somapacitan in Children and Adolescents with Idiopathic Short Stature: 2-Year REAL8 Results Including Switch from Daily GH (ESPE 2026) - No abstract available

Clinical • Idiopathic Short Stature

Once-weekly somapacitan enhances linear growth in girls with Turner syndrome: a randomized controlled phase 3 study. (PubMed, J Clin Endocrinol Metab) - P3 | "Once-weekly somapacitan showed non-inferiority and is comparable to daily GH after 52 weeks of treatment in enhancing linear growth while maintaining IGF-I concentrations within a similar range in treatment-naïve girls with TS. Similar safety profiles and tolerability were observed for both groups."

Journal • P3 data • Genetic Disorders • Turners Syndrome • IGF1

Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials. (PubMed, Endocrinol Diabetes Metab) - "Once-weekly LAGH provides an effective frontline alternative to daily acting growth hormone, without compromising overall linear growth or safety, while displaying no differences in overall treatment discontinuation. Selection should be based on the patients' clinical profiles, specifically considering higher localized reactions with Somatrogon. Clinicians should adhere to formulation-specific sampling windows (2-5 days post dose for Lonapegsomatropin; 96 h for Somatrogon) to accurately monitor steady-state IGF-1 levels."

Clinical • Journal • Retrospective data • Review • Dermatology • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pain • Pediatrics • IGF1

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes. (PubMed, J Endocr Soc) - P1, P2, P3 | "Somapacitan 0.24 mg/kg/week produced similar IGF-I SDS changes and height velocity increases as daily GH in prepubertal short children and adolescents born SGA or with ISS, NS, or TS. The results support that the guidance already established for GHD regarding somapacitan initiation, dosing flexibility, and IGF-I monitoring remain appropriate for prepubertal short children and adolescents born SGA or with ISS, NS, or TS."

Journal • Genetic Disorders • Idiopathic Short Stature • Small for Gestational Age • Turners Syndrome • IGF1

Heterogeneity In Severe Adult Growth Hormone Deficiency (ENDO 2026) - "However, ITT and GHRP-2 test showed severe adult GH deficiency, and then somapacitan, SGLT-2 inhibitor and Tirzepatide treatments improved cognitive function (HDS-R: 5 to 28 points), decreasing in body weight and diabetes mellitus. These different three cases indicated that patients with severe GH deficiency in early stage should be found and treatment with replenishment of growth hormone in early stage to protect development of lifestyle-related diseases such as fatty liver, glucose intolerance, obesity, depression and the disturbance of cognitive function."

Clinical • Heterogeneity • Anorexia • Brain Cancer • CNS Disorders • CNS Tumor • Depression • Diabetes • Endocrine Disorders • Genetic Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Hepatology • Liver Failure • Meningioma • Metabolic Disorders • Obesity • Pituitary Gland Carcinoma • Solid Tumor

Somapacitan (Sogroya) will be listed for the first time to treat children with growth hormone deficiency (GHD) (Australian Government Department of Health) - "Sogroya is a long-acting growth hormone treatment taken weekly which helps to support normal growth while removing the need for daily injections. More than 650 Australian children are expected to benefit from this listing each year. Without the PBS subsidy, patients might pay more than $650 per pack."

Reimbursement • Growth Hormone Deficiency (Pediatric)

Efficacy and Safety of Somapacitan vs Daily Growth Hormone in Children with Growth Hormone Deficiency: A Pooled Analysis of Randomised Trial Data. (PubMed, Horm Res Paediatr) - "In this pooled analysis of clinical trial data, somapacitan demonstrated similar efficacy and safety to daily GH for up to 156 weeks' treatment. A dose of 0.16 mg/kg/week of somapacitan was able to maintain consistent growth in children and adolescents who reached puberty."

Journal • Retrospective data • Endocrine Disorders • Growth Hormone Deficiency

Effects of switching from somatropin to somapacitan on thyroid hormone levels in adult growth hormone deficiency: A pilot study. (PubMed, Growth Horm IGF Res) - "Multiple regression identified baseline FT4, rather than levothyroxine use, as independently associated with ΔFT4. These findings suggest the need for careful monitoring of FT4 and potential adjustment of thyroid hormone replacement during somapacitan therapy."

Journal • Cardiovascular • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • IGF1

Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients. (PubMed, Front Pediatr) - "Subgroup analyses were performed based on LAGH platform (PEG-LAGH, somatrogon, somapacitan, lonapegsomatropin) and treatment duration. Among children with isolated GHD, LAGH represents the preferred platform, offering both superior first-year height velocity and acceptable safety. In contrast, newer prodrug or albumin-binding LAGH formulations provide injection convenience but lack superior growth efficacy."

Journal • Retrospective data • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pediatrics • IGF1

Injection-Site Pain with Two Once-Weekly Growth Hormone Products in Children: A Sequential within-Subject Comparison of Somatrogon and Somapacitan (ENDO 2026) - "In pediatric patients experiencing injection-site pain with somatrogon, switching to somapacitan resulted in significant pain reduction in a within-subject comparison. These findings support the clinical importance of formulation choice and may facilitate shared decision-making in pediatric growth hormone therapy."

Clinical • Brain Cancer • CNS Tumor • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Pediatric) • Pain

Metabolic and endocrinological effects of weekly growth hormone replacement therapy with somapacitan in patients with adult growth hormone deficiency after switching from daily growth hormone replacement therapy: A real-world exploratory cohort study. (PubMed, Drug Discov Ther) - "Switching to GH replacement therapy did not affect endocrinological parameters. These findings, which were revealed by the present real-world exploratory cohort study, indicate that weekly GH replacement therapy with somapacitan may confer more beneficial effects than daily GH replacement therapy."

Journal • Real-world evidence • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult)

BUDGET IMPACT MODEL OF LONAPEGSOMATROPIN FOR THE TREATMENT OF ADULT GROWTH HORMONE DEFICIENCY IN THE UNITED STATES (ISPOR 2026) - "Lonapegsomatropin is budget‑neutral to budget‑favorable during the 5-year period investigated, when replacing somapacitan. These findings support the economic viability of expanding the indication for lonapegsomatropin to AGHD. Future work should incorporate net prices/rebates and treatment‑specific utilization linked to persistence/adherence to refine payer‑relevant estimates."

Clinical • HEOR • Endocrine Disorders • Growth Hormone Deficiency • Growth Hormone Deficiency (Adult) • Growth Hormone Deficiency (Pediatric)